Altimmune Selloff On Clinical Hold A Buying Opportunity, Says JMP Securities

After speaking with management, JMP Securities analyst Jonathan Wolleben expects Altimmune (ALT) to resolve the AdCOVID IND clinical hold in early January with Phase 1 data still expected in Q1.

Management confirmed that the clinical hold was related to four issues: three clinical protocol issues, all of which have been resolved, and one related to a manufacturing test procedure for which Altimmune expects data in early January, Wolleben tells investors in a research note. The hold does not change the analyst's view that AdCOVID is a "differentiated" COVID-19 vaccine candidate.

He views any weakness in Altimmune shares as a buying opportunity and reiterates an Outperform rating on the name with a $50 price target. The stock in premarket trading is down 9% to $11.43.


Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.